Department of Hematology, The First Hospital of China Medical University, 110001 Shenyang, Liaoning, China.
Anhui Province Key Laboratory of Medical Physics and Technology, Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, 230031 Hefei, Anhui, China.
Front Biosci (Landmark Ed). 2024 Feb 22;29(2):86. doi: 10.31083/j.fbl2902086.
The term 'liquid biopsy' has become widely used by clinicians with the development of non-invasive diagnostic and monitoring techniques for malignancies. Liquid biopsy can provide genetic information for early diagnosis, risk stratification, treatment selection and postoperative follow-up. In the era of personalized medicine, liquid biopsy is an important research direction. In recent years, research on circulating tumour DNA (ctDNA) in hematological malignancies has also made great progress. This review provides an overview of the current understanding of circulating tumour DNA in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Additionally, recent advancements in the monitoring of minimal/measurable residual disease (MRD) through ctDNA are discussed.
随着恶性肿瘤非侵入性诊断和监测技术的发展，“液体活检”一词已被临床医生广泛使用。液体活检可为早期诊断、风险分层、治疗选择和术后随访提供遗传信息。在个性化医疗时代，液体活检是一个重要的研究方向。近年来，血液系统恶性肿瘤中循环肿瘤 DNA（ctDNA）的研究也取得了很大进展。本文综述了目前对骨髓增生异常综合征（MDS）和急性髓系白血病（AML）中循环肿瘤 DNA 的认识，并讨论了通过 ctDNA 监测微小残留病（MRD）的最新进展。
